Literature & Presentations
Peer-reviewed publications or conference presentations are available to read here
Date Range
Explore
Search
Non-Small Cell Lung Cancer / 03 Aug 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Zhao. Y et al. eClinicalMedicine (Part of The Lancet Discovery Science), Vol 62. 2023
Non-Small Cell Lung Cancer / 04 Jun 2023
Phase II results of Ivonescimab (AK112/SMT112) a novel PD-1/VEGF bispecific in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK
L. Zhang et al. ASCO 2023
Non-Small Cell Lung Cancer / 12 Nov 2022
AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies
T. Zhong et al. SITC 2022
Non-Small Cell Lung Cancer / 03 Jun 2022
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first or second-line therapy for advanced non-small cell lung cancer (NSCLC)
C. Zhou et al. ASCO 2022
Non-Small Cell Lung Cancer / 03 Jun 2022
A phase II study of AK112 (PD-1/VEGF Bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Y.Zhao et al. ASCO 2022